Nanotechnology approaches for inhalation treatment of fibrosis.
Nanotechnology approaches for inhalation treatment of fibrosis.
复制标题
DOI：
10.3109/1061186x.2013.829078
复制
发表时间：
2013-12
影响因子：
4.5
通讯作者：
Minko T
中科院分区：
文献类型：
--
作者：
Savla R;Minko T
囊性纤维化（CF）是一种常染色体隐性单基因遗传疾病，困扰着全球近70000例患者。这种突变导致多个器官中的粘性粘液积累，特别是在肺、肝和胰腺中。由于缺乏有效的治疗方法，CF导致高相关发病率和死亡率。人们普遍认为CF引起的发病率和死亡率主要是由于该疾病的呼吸系统表现。因此，最近开发了几种方法来治疗CF的肺部并发症。然而，缺乏有效的递送方法，特别是将治疗剂特异性地靶向递送至肺组织和细胞，限制了治疗的效率。治疗剂的局部肺部递送相对于全身应用具有两个主要优点。首先，它增强了治疗剂在肺部的积累，从而提高了治疗效率。其次，局部肺递送基本上防止了递送的药物渗透到体循环中，限制了治疗对其他器官和组织的不良副作用。这篇评论的重点是不同的方法来治疗CF的呼吸系统表现，以及对肺部输送的治疗方法。
Cystic fibrosis (CF) is an autosomal recessive monogenetic disease that afflicts nearly 70 000 patients worldwide. The mutation results in the accumulation of viscous mucus in multiple organs especially in the lungs, liver and pancreas. High associated morbidity and mortality is caused by CF due to the lack of effective therapies. It is widely accepted that morbidity and mortality caused by CF is primarily due to the respiratory manifestations of the disease. Consequently, several approaches were recently developed for treatment of lung complications of CF. However, the lack of effective methods for delivery and especially targeted delivery of therapeutics specifically to lung tissues and cells limits the efficiency of the therapy. Local pulmonary delivery of therapeutics has two major advantages over systemic application. First, it enhances the accumulation of therapeutics specifically in the lungs and therefore increases the efficiency of the treatment. Second, local lung delivery substantially prevents the penetration of the delivered drug into the systemic circulation limiting adverse side effects of the treatment on other organs and tissues. This review is focused on different approaches to the treatment of respiratory manifestations of CF as well as on methods of pulmonary delivery of therapeutics.